Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. LEDERTREXATE (methotrexate)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • Warning

    You need to be authenticated to perform this action

    No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

LEDERTREXATE (methotrexate)

Medicine - Posted on Apr 21 2016 - Updated on Jun 12 2019
Active substance (DCI)
  • methotrexate
history (3)
  • 4/6/16

    METHOTREXATE BIODIM - LEDERTREXATE (methotrexate)

    Avis défavorable au maintien de la prise en charge dans les adénocarcinomes ovariens et les carcinomes bronchiques à petites...
    icône flèche
  • 11/18/09

    LEDERTREXATE (methotrexate)

    LEDERTREXATE (methotrexate)
    CAV :
    54321
    icône flèche
  • 3/1/06

    LEDERTREXATE 25 mg, solution injectable Ampoule de 1 ml (316 021-8) LEDERTREXATE 5 mg, solution injectable Ampoule de 2 ml (315 012-5) LEDERTREXATE 50 mg, solution injectable Ampoule de 2 ml (315 014-8)

    LEDERTREXATE 25 mg, solution injectable Ampoule de 1 ml (316 021-8) LEDERTREXATE 5 mg, solution injectable Ampoule de 2 ml (315 012-5) LEDERTREXATE 50 mg, solution injectable Ampoule de 2 ml (315 014-8)
    icône flèche
Technical information
ATC code
  • L01BA01
Manufacturer
BIODIM
Presentation

LEDERTREXATE 5 mg, solution injectable
1 ampoule en verre de 2 ml (CIP : 315 012-5)

LEDERTREXATE 25 mg, solution injectable
1 ampoule en verre de 1 ml (CIP : 316 021-8)

LEDERTREXATE 50 mg, solution injectable
Ampoule de 2 ml (CIP : 34009 315 014 8 0)

All our publications
    Autoimmune diseases Bone cancers Breast cancers Cancers - miscellaneous Drug therapy Genital cancers Hematologic cancers Joint and rheumatic diseases Nervous system cancers Respiratory tract cancers Skin and connective tissue diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
QwWXkVucSBr2CSHc